Nevertheless, understanding how L‐OPA1 processing varies in syndromic OPA1 and common diseases of dopaminergic cell loss such as Parkinson's and promoting L‐OPA1 stability (eg, by OMA1 inhibition) could pave the way for novel targeted therapies against mitochondrial dysfunction in neurodegeneration. Here, OPA1 is linked to Parkinson disease.